Claims for Patent: 9,663,510

Summary for Patent: 9,663,510

Title:	Substituted triazolopyridines and their use as TTK inhibitors
Abstract:	The present invention relates to substituted triazolopyridine compounds of general formula (I): ##STR00001## in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, and R.sup.5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.
Inventor(s):	Schulze; Volker (OT Bergfelde, DE), Kosemund; Dirk (Berlin, DE), Wengner; Antje Margret (Berlin, DE), Siemeister; Gerhard (Berlin, DE), Stockigt; Detlef (Potsdam, DE), Bruning; Michael (Schildow, DE)
Assignee:	BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE) BAYER INTELLECTUAL PROPERTY GMBH (Monheim, DE)
Application Number:	14/362,836
Patent Claims:	1. A compound of formula (I): ##STR00261## wherein: R.sup.1 is ##STR00262## wherein * indicates the point of attachment of said group to the rest of the molecule; R.sup.2 is ##STR00263## wherein * indicates the point of attachment of said group to the rest of the molecule; R.sup.3 is a hydrogen atom; R.sup.4 is a hydrogen atom; R.sup.5 is a hydrogen atom or a C.sub.1-C.sub.3-alkyl- group; R.sup.5a is a group selected from: C.sub.1-C.sub.4-alkoxy-, halo-C.sub.1-C.sub.4-alkoxy-, and C.sub.1-C.sub.4-alkyl; R.sup.5b is a group selected from: --C(.dbd.O)N(H)R.sup.8, --C(.dbd.O)NR.sup.8R.sup.7, --N(R.sup.7)C(.dbd.O)OR.sup.8, and R.sup.7--S(.dbd.O).sub.2--; R.sup.6 is a ##STR00264## wherein * indicates the point of attachment of said group to the rest of the molecule, and wherein said group is optionally substituted, one or more times, identically or differently, with a halogen atom or a methyl- group; R.sup.7 is a C.sub.1-C.sub.3-alkyl- or a cyclopropyl- group; R.sup.8 is a hydrogen atom or a C.sub.1-C.sub.6-alkyl- or C.sub.3-C.sub.6-cycloalkyl- group, wherein said C.sub.1-C.sub.6-alkyl- or C.sub.3-C.sub.6-cycloalkyl- group is optionally substituted, one or more times, with a halogen atom; or R.sup.7 and R.sup.8 together with the molecular fragment to which they are attached form a 4- to 6-membered heterocyclic ring, which is optionally substituted, one or more times, identically or differently, with a halogen atom, a C.sub.1-C.sub.3-alkyl-, halo-C.sub.1-C.sub.3-alkyl- or C.sub.1-C.sub.3 alkoxy- group, or a hydroxyl group; R.sup.9 is a group selected from: C.sub.1-C.sub.3-alkyl-, hydroxy-C.sub.1-C.sub.3-alkyl, --N(H)R.sup.8, --N(R.sup.7)R.sup.8, N(H)(R.sup.8)--C.sub.1-C.sub.3-alkyl-, and N(R.sup.7)(R.sup.8)--C.sub.1-C.sub.3-alkyl-; and Q is CH or N, or a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of any of the foregoing. 2. The compound according to claim 1, wherein: R.sup.5 is a hydrogen atom, or a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of any of the foregoing. 3. The compound according to claim 1, wherein: Q is CH, or a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of any of the foregoing. 4. The compound according to claim 1, wherein: R.sup.5a is a group selected from: C.sub.1-C.sub.2-alkoxy- and halo-C.sub.1-C.sub.2-alkoxy-, or a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of any of the foregoing. 5. The compound according to claim 1, wherein: R.sup.6 is a ##STR00265## wherein * indicates the point of attachment of said group to the rest of the molecule, or a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of any of the foregoing. 6. The compound according to claim 1, wherein: R.sup.9 is a group selected from: methyl-, hydroxy-C.sub.1-C.sub.2-alkyl-, --NH.sub.2, --N(R.sup.10)R.sup.10, and --C.sub.1-C.sub.2-alkyl-N(R.sup.10)R.sup.10; and R.sup.10 is a hydrogen atom or a methyl- group, or a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of any of the foregoing. 7. The compound according to claim 1, wherein: R.sup.9 is a group selected from: methyl-, hydroxy-methyl-, and --NH.sub.2, or a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of any of the foregoing. 8. A compound according to claim 1, wherein: R.sup.5b is a group selected from: --C(.dbd.O)N(H)R.sup.8 and --C(.dbd.O)NR.sup.8R.sup.7; R.sup.7 is a C.sub.1-C.sub.3-alkyl- group; and R.sup.8 is a hydrogen atom or a C.sub.1-C.sub.3-alkyl- group, wherein said C.sub.1-C.sub.3-alkyl- group is optionally substituted, one or more times, with a halogen atom; or R.sup.7 and R.sup.8 together with the molecular fragment to which they are attached form a 4- to 6-membered heterocyclic ring, which is optionally substituted, one or more times, identically or differently, with a halogen atom, or a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of any of the foregoing. 9. The compound according to claim 1, wherein: R.sup.5b is a --N(R.sup.7)C(.dbd.O)OR.sup.8 group; and R.sup.7 and R.sup.8 together with the molecular fragment to which they are attached form a 4- to 6-membered heterocyclic ring, or a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of any of the foregoing. 10. The compound according to claim 1, wherein: R.sup.5b is a R.sup.7--S(.dbd.O).sub.2-- group; and R.sup.7 is a C.sub.1-C.sub.3-alkyl- group, or a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of any of the foregoing. 11. The compound according to claim 1, which is selected from the group consisting of: (2R)-2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(methylsulfonyl)phenyl]amin- o}[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl]propanamide; (2R)--N-[4-(2-{[2-ethoxy-4-(methylsulfonyl)phenyl]amino}[1,2,4]triazolo[1- ,5-a]pyridin-6-yl)phenyl]-2-(4-fluorophenyl)propanamide; (2R)-2-(4-fluorophenyl)-N-[4-(2-{[4-(methylsulfonyl)-2-(2,2,2-trifluoroet- hoxy)-phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl]propanamide; 4-{[6-(4-{[(2R)-2-(4-fluorophenyl)propanoyl]amino}phenyl)[1,2,4]triazolo [1,5-a]pyridin-2-yl]amino}-3-methoxy-N-(2,2,2-trifluoroethyl)benzamide; 4-{[6-(4-{[(2R)-2-(4-fluorophenyl)propanoyl]amino}phenyl)[1,2,4]triazolo [1,5-a]pyridin-2-yl]amino}-3-methoxybenzamide; 4-{[6-(4-{[(2R)-2-(4-fluorophenyl)propanoyl]amino}phenyl)[1,2,4]triazolo [1,5-a]pyridin-2-yl]amino}-3-(2,2,2-trifluoroethoxy)benzamide; (2R)--N-{4-[2-({4-[(3-fluoroazetidin-1-yl)carbonyl]-2-methoxyphenyl}amino- )[1,2,4]triazolo [1,5-a]pyridin-6-yl]phenyl}-2-(4-fluorophenyl)propanamide; (2R)--N-[4-(2-{[4-(azetidin-1-ylcarbonyl)-2-methoxyphenyl]amino}[1,2,4]tr- iazolo[1,5-a]pyridin-6-yl)phenyl]-2-(4-fluorophenyl)propanamide; (2R)-2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(2-oxo-1,3-oxazolidin-3-yl)- phenyl]-amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl]propanamide; (-)-2-(4-fluorophenyl)-3-hydroxy-N-[4-(2-{[4-(methylsulfonyl)-2-(2,2,2-tr- i-fluoroethoxy)phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl]prop- anamide; (2R)-2-amino-2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(methylsulf- onyl)-phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl]ethanamide; 4-{[6-(4-{[(2R)-2-(4-fluorophenyl)propanoyl]amino}phenyl)[1,2,4]triazolo [1,5-a]pyridin-2-yl]amino}-3-methoxy-N,N-dimethylbenzamide; (2R)-2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(pyrrolidin-1-ylcarbonyl)ph- enyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl]propanamide; (2R)--N-{4-[2-({4-[(3-fluoroazetidin-1-yl)carbonyl]-2-(2,2,2-trifluoroeth- oxy)phenyl}amino)[1,2,4]triazolo[1,5-a]pyridin-6-yl]phenyl}-2-(4-fluorophe- nyl)propanamide; (2R)-2-(4-fluorophenyl)-N-{4-[2-({4-[(3-hydroxyazetidin-1-yl)carbonyl]-2-- (2,2,2-trifluoroethoxy)phenyl}amino)[1,2,4]triazolo[1,5-a]pyridin-6-yl]phe- nyl}propanamide; (2R)-2-(4-fluorophenyl)-N-[4-(2-{[4-(pyrrolidin-1-ylcarbonyl)-2-(2,2,2-tr- ifluoroethoxy)phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl]propa- namide; (2S)-2-(4-fluorophenyl)-3-hydroxy-N-[4-(2-{[2-methoxy-4-(methylsul- fonyl)phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl]propanamide; (2S)--N-{4-[2-({4-[(3-fluoroazetidin-1-yl)carbonyl]-2-(2,2,2-trifluoroeth- oxy)phenyl}amino)[1,2,4]triazolo[1,5-a]pyridin-6-yl]phenyl}-2-(4-fluorophe- nyl)-3-hydroxypropanamide; (2R)-2-amino-2-(4-fluorophenyl)-N-[4-(2-{[4-(methylsulfonyl)-2-(2,2,2-tri- fluoroethoxy)phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl]ethana- mide; (2R)-2-amino-2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(2-oxo-1,3-oxa- zolidin-3-yl)phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl]ethana- mide; (2R)-2-amino-N-{4-[2-({4-[(3-fluoroazetidin-1-yl)carbonyl]-2-methoxy- phenyl}amino)[1,2,4]triazolo[1,5-a]pyridin-6-yl]phenyl}-2-(4-fluorophenyl)- ethanamide; (2R)-2-amino-N-[4-(2-{[4-(azetidin-1-ylcarbonyl)-2-methoxyphenyl]amino}[1- ,2,4]triazolo [1,5-a]pyridin-6-yl)phenyl]-2-(4-fluorophenyl)ethanamide; (2R)-2-amino-2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(pyrrolidin-1-ylcar- bonyl)phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl]ethanamide; (2R)-2-amino-N-{4-[2-({4-[(3-fluoroazetidin-1-yl)carbonyl]-2-(2,2,2-trifl- uoroethoxy)phenyl}amino)[1,2,4]triazolo [1,5-a]pyridin-6-yl]phenyl}-2-(4-fluorophenyl)ethanamide; and (2R)-2-amino-2-(4-fluorophenyl)-N-[4-(2-{[4-(pyrrolidin-1-ylcarbonyl)-2-(- 2,2,2-trifluoroethoxy)phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)phen- yl]ethanamide, or a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of any of the foregoing. 12. A method of preparing the compound of formula (I) according to claim 1, comprising reacting an intermediate compound of formula (5): ##STR00266## wherein R.sup.1, R.sup.3, R.sup.4, and R.sup.5 are as defined in claim 1, with a compound of formula (5a): R.sup.2--Y (5a) wherein R.sup.2 is as defined in claim 1, and Y is a leaving group, to provide the compound of formula (I). 13. A method of preparing the compound of formula (I) according to claim 1, comprising reacting an intermediate compound of formula (5): ##STR00267## wherein R.sup.5, R.sup.6, and R.sup.9 are as defined in claim 1, with an aryl compound of formula (5a): R.sup.2--Y (5a) wherein R.sup.2 is as defined in claim 1, and Y is a leaving group, to provide a compound of formula (Ia): ##STR00268## wherein R.sup.2, R.sup.5, R.sup.6, and R.sup.9 are as defined in claim 1; and optionally separating the compound of formula (I) from a compound of formula (Ib): ##STR00269## wherein R.sup.2, R.sup.5, R.sup.6, and R.sup.9 are as defined in claim 1. 14. A method of preparing the compound of formula (I) according to claim 1, comprising reacting an intermediate compound of formula (7): ##STR00270## wherein R.sup.2, R.sup.3, R.sup.4, and R.sup.5 are as defined in claim 1, and R.sup.1a is a phenyl group to which an --NH.sub.2 substituent is bound in para position, with a compound of formula (7a): ##STR00271## wherein R.sup.9 and R.sup.6 are as defined in claim 1, and X is a suitable functional group, via which the R.sup.1b of the R.sup.1b--X compound (7a) can be coupled, via a coupling reaction, onto the --NH.sub.2 substituent bound to the phenyl group R.sup.1a of compound (7), to provide the compound of formula (I). 15. A method of preparing the compound of formula (I) according to claim 1, comprising reacting an intermediate compound of formula (7): ##STR00272## wherein R.sup.2, R.sup.3, R.sup.4, and R.sup.5 are as defined in claim 1, and R.sup.1a is a phenyl group to which an --NH.sub.2 substituent is bound in the para position, with a compound of formula (7a): ##STR00273## wherein R.sup.9 and R.sup.6 are as defined in claim 1, and X is a suitable functional group, via which the --C(O)C(H)R.sup.6R.sup.9 group of compound (7a) can be coupled, via a coupling reaction onto the --NH.sub.2 substituent bound to the phenyl group R.sup.1a of compound (7), to provide a compound of formula (Ia): ##STR00274## and optionally separating the compound of formula (I) from a compound of formula (Ib): ##STR00275## 16. A pharmaceutical composition comprising the compound according to claim 1, or a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a mixture of any of the foregoing, and a pharmaceutically acceptable diluent or carrier. 17. A pharmaceutical combination comprising: one or more compounds according to claim 1, or a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a mixture of any of the foregoing; and one or more agents selected from: a taxane, Docetaxel, Paclitaxel, or Taxol; an epothilone, Ixabepilone, Patupilone, or Sagopilone; Mitoxantrone; Predinisolone; Dexamethasone; Estramustin; Vinblastin; Vincristin; Doxorubicin; Adriamycin; Idarubicin; Daunorubicin; Bleomycin; Etoposide; Cyclophosphamide; Ifosfamide; Procarbazine; Melphalan; 5-Fluorouracil; Capecitabine; Fludarabine; Cytarabine; Ara-C; 2-Chloro-2'-deoxyadenosine; Thioguanine; an anti-androgen, Flutamide, Cyproterone acetate, or Bicalutamide; Bortezomib; a platinum derivative, Cisplatin, or Carboplatin; Chlorambucil; Methotrexate; and Rituximab. 18. A method for the treatment of a disease of uncontrolled cell growth, proliferation or survival, cellular immune response, or cellular inflammatory response, which is responsive to inhibition of Mps-1 kinase activity comprising administering to a patient in need thereof a therapeutically effective amount of the compound according to claim 1 or a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a mixture of the foregoing. 19. The method of claim 18, wherein the disease of uncontrolled cell growth, proliferation or survival, cellular immune response, or cellular inflammatory response is a haemotological tumour, a solid tumour or metastases thereof. 20. The method of claim 19, wherein the haemotological tumour, solid tumour or metastases thereof is selected from leukemias and myelodysplastic syndrome, malignant lymphomas, head and neck tumours, brain tumours and brain metastases, tumours of the thorax, non-small cell and small cell lung tumours, gastrointestinal tumours, endocrine tumours, mammary and other gynaecological tumours, urological tumours, renal, bladder and prostate tumours, skin tumours, and sarcomas, or metastases thereof. 21. The method according to claim 18, wherein the disease of uncontrolled cell growth, proliferation or survival, cellular immune response, or cellular inflammatory response is cervical cancer. 22. A method for the inhibition of Mps-1 kinase activity comprising contacting a target cell with an effective amount of the compound according to claim 1 or a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a mixture of any of the foregoing. 23. The compound according to claim 1, wherein the compound is: (2R)-2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(methylsulfonyl)phenyl]amin- o}[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl]propanamide, or a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a mixture of any of the foregoing. 24. The compound according to claim 1, wherein the compound is: (2R)-2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(methylsulfonyl)phenyl]amin- o}[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl]propanamide, or a pharmaceutically acceptable salt thereof. 25. A pharmaceutical composition comprising (2R)-2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(methylsulfonyl)phenyl]amin- o}-[1,2,4]triazolo [1,5-a]pyridin-6-yl)phenyl]propanamide, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier. 26. The pharmaceutical composition of claim 25, further comprising one or more agents selected from a taxane, an epothilone, an anti-androgen or a platinum derivative. 27. The pharmaceutical composition of claim 25, further comprising one or more agents selected from the group consisting of Docetaxel, Paclitaxel, Taxol, Ixabepilone, Patupilone, Sagopilone, Mitoxantrone, Predinisolone, Dexamethasone, Estramustin, Vinblastin, Vincristin, Doxorubicin, Adriamycin, Idarubicin, Daunorubicin, Bleomycin, Etoposide, Cyclophosphamide, Ifosfamide, Procarbazine, Melphalan, 5-Fluorouracil, Capecitabine, Fludarabine, Cytarabine, Ara-C, 2-Chloro-2'-deoxyadenosine, Thioguanine, Flutamide, Cyproterone acetate, Bicalutamide, Bortezomib, Cisplatin, Carboplatin, Chlorambucil, Methotrexate and Rituximab.

Details for Patent 9,663,510

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2031-12-12
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2031-12-12
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2031-12-12